Recursion Pharmaceuticals (RXRX) EBITDA (2020 - 2026)

Recursion Pharmaceuticals has reported EBITDA for 7 years, with the latest figure at -$128.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 32.85% year-over-year to -$128.5 million; the trailing twelve-month figure through Mar 2026 stood at -$585.3 million (down 2.95% YoY), and the FY2025 full-year result was -$648.1 million, down 35.31% from the prior year.
• EBITDA for Q1 2026 stood at -$128.5 million, down from -$108.3 million in the prior quarter.
• The five-year high for EBITDA was -$56.0 million in Q1 2022, with the low at -$191.4 million in Q1 2025.
• Historically, EBITDA has averaged -$107.3 million across 5 years, with a median of -$95.8 million in 2024.
• The largest YoY upside for EBITDA was 41.05% in 2025 against a maximum downside of 109.44% in 2025.
• Recursion Pharmaceuticals' EBITDA stood at -$61.0 million in 2022, then tumbled by 62.23% to -$98.9 million in 2023, then tumbled by 85.76% to -$183.8 million in 2024, then jumped by 41.05% to -$108.3 million in 2025, then dropped by 18.62% to -$128.5 million in 2026.
• The last three EBITDA figures came in at -$128.5 million (Q1 2026), -$108.3 million (Q4 2025), and -$172.2 million (Q3 2025), per Business Quant data.